Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus

被引：23

作者：

Fitzgibbon, JE

John, JF

Delucia, JL

Dubin, DT

机构：

[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA

[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Allergy Immunol & Infect Dis, Piscataway, NJ 08854 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1998年 / 42卷 / 08期

关键词：

D O I：

10.1128/AAC.42.8.2122

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A total of 201 Staphylococcus aureus isolates were surveyed for susceptibility to ciprofloxacin and trovafloxacin. Of 66 methicillin-resistant isolates, 89% were ciprofloxacin resistant and 6% were also trovafloxacin resistant. Trovafloxacin-resistant strains had unusual patterns of quinoline resistance mutations in DNA topoisomerase genes, including two mutations in the A subunit (encoded by grlA) of topoisomerase IV.

引用

页码：2122 / 2124

页数：3

共 18 条

[1] Trends in bacterial resistance to fluoroquinolones
Acar, JF
Goldstein, FW
[J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 : S67 - S73
[2] Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin
Bonilla, HF
Zarins, LT
Bradley, SF
Kauffman, CA
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 26 (01) : 17 - 21
[3] ANTISTAPHYLOCOCCAL ACTIVITIES OF SPARFLOXACIN (CI-978-AT-4140), OFLOXACIN, AND CIPROFLOXACIN
CHAUDHRY, AZ
KNAPP, CC
SIERRAMADERO, J
WASHINGTON, JA
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) : 1843 - 1845
[4] Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae
Deguchi, T
Fukuoka, A
Yasuda, M
Nakano, M
Ozeki, S
Kanematsu, E
Nishino, Y
Ishihara, S
Ban, Y
Kawada, Y
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) : 699 - 701
[5] DNA gyrase, topoisomerase IV, and the 4-quinolones
Drlica, K
Zhao, XL
[J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) : 377 - +
[6] Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections
Endtz, HP
Mouton, JW
denHollander, JG
vandenBraak, N
Verbrugh, HA
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 1146 - 1149
[7] CLONING AND PRIMARY STRUCTURE OF STAPHYLOCOCCUS-AUREUS DNA TOPOISOMERASE-IV - A PRIMARY TARGET OF FLUOROQUINOLONES
FERRERO, L
CAMERON, B
MANSE, B
LAGNEAUX, D
CROUZET, J
FAMECHON, A
BLANCHE, F
[J]. MOLECULAR MICROBIOLOGY, 1994, 13 (04) : 641 - 653
[8] ANALYSIS OF GYRA AND GRLA MUTATIONS IN STEPWISE-SELECTED CIPROFLOXACIN-RESISTANT MUTANTS OF STAPHYLOCOCCUS-AUREUS
FERRERO, L
CAMERON, B
CROUZET, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) : 1554 - 1558
[9] Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli
Heisig, P
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) : 879 - 885
[10] PRELIMINARY INTERPRETIVE CRITERIA FOR IN-VITRO SUSCEPTIBILITY TESTING OF CP-99219 BY DILUTION AND DISK DIFFUSION METHODS
JONES, RN
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 20 (03) : 167 - 170

← 1 2 →